Teva Pharmaceuticals (TEVA, +0.47%) announced on Thursday that they had reached a settlement with Nevada and resolved their nationwide settlement agreement relating to opioid claims made by states. The company will settle the case with Nevada by paying $193 million in 20 years. This is ahead of an August trial. Teva said that it has settled its opioid litigation in all 50 states, as well as with more than 99% litigating subdivisions, special districts and other entities. The company expects to pay its first payment in the second half this year. The company stated that the final agreement does not include any admissions of wrongdoing. Teva said it has begun shipping generic Narcan – an opioid overdose treatment – and that shipments will increase next year, as part of a settlement agreement. Teva’s shares rose 1.4% in premarket trading on Thursday.